# Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial

> **NCT01655212** · PHASE3 · TERMINATED · sponsor: **Dr. Ann C.T.M. Vossen** · enrollment: 2 (actual)

## Conditions studied

- Congenital Cytomegalovirus Infection
- Sensorineural Hearing Loss

## Interventions

- **DRUG:** Valganciclovir

## Key facts

- **NCT ID:** NCT01655212
- **Lead sponsor:** Dr. Ann C.T.M. Vossen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-06
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** 1 Indication for further investigations (brain ultrasound). 2 Change of study design to efficacy study with historical control group.
- **Last updated:** 2015-06-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01655212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01655212, "Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01655212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*